Selective cell therapy for the treatment of renal failure

• US 10,590,391 B2
• Filed: 11/13/2009
• Issued: 03/17/2020
• Est. Priority Date: 06/08/2007
• Status: Active Grant

• Current Assignee: Wake Forest University Health Sciences
• Original Assignee: Wake Forest University Health Sciences
• Inventors: Atala, Anthony, Yoo, James J.
• Primary Examiner(s): Epps-Smith, Janet L
• Application Number:
  US12/618,179
• Publication Number:
  US 20100104544A1
• Time in Patent Office: 3,777 Days
• Field of Search: 424 937, 424423, 435369, 435373, 435375
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 2500/02 Atmosphere, e.g. low oxygen conditions
• CPC Class Codes: C12N 5/0686 Kidney cells

Abstract

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.

Claims

1. A composition suitable for administration to the kidney of a subject comprising a population of differentiated mammalian renal cells harvested from the subject'"'"'s kidney and passaged in vitro from 2 to 9 times to expand their number, wherein the population comprises renal cells that produce erythropoietin (EPO) in co-culture with other cortical renal cell types, and a pharmaceutically acceptable carrier,

wherein:

(i) the renal cells produce EPO under normoxic conditions, and

(ii) the cells that produce EPO and the other cortical renal cell types have not been manipulated by the introduction of an exogenous gene that stimulates the production of EPO or by an exogenous chemical that stimulates the production of EPO,

subject to the proviso that said cells that produce EPO and other cortical renal cell types are not transfected with an exogenous DNA encoding a polypeptide,

wherein said population has oxygen tension-dependent EPO expression such that the cells that produce EPO have a 2- to 20-fold increase in EPO expression as measured by an increase in EPO mRNA when under hypoxic conditions as compared to normoxic conditions, and have a 2- to 20-fold decrease in EPO expression as measured by a decrease in EPO mRNA expression when cells return to normoxic conditions from hypoxic conditions,

wherein said pharmaceutically acceptable carrier comprises a hydrogel,

wherein said composition comprises from 1×

10⁵ to 1×

10⁹ total renal cells, and

wherein said population expresses EPO in vivo upon administration to the subject.

2. The composition of claim 1, wherein said cells that produce EPO have an increase in EPO expression as measured by a 2- to 20-fold increase in EPO mRNA after incubation of said cells at 70% confluency for 24 hours:

under hypoxic conditions of;

a humidified incubator at 37°

C., at atmospheric pressure, and with 1% O₂, 5% CO₂ and 94% N₂,

as compared to incubation under normoxic conditions of;

a humidified incubator at 37°

C., at atmospheric pressure, and with 5% CO₂ and 95% atmospheric air,

wherein said incubation media is a 1;

1 mixture of keratinocyte serum-free medium (KSFM) and premixed Dulbecco'"'"'s Modified Eagle'"'"'s Medium (DMEM) based media, wherein said DMEM based media is ¾

DMEM and ¼

HAM'"'"'s F12 nutrient mixture supplemented with 5% fetal bovine serum (FBS), 1% Penicillin/Streptomycin, 1% glutamine 100×

, 1 ml of 0.4 μ

g/ml hydrocortisone, 0.5 ml of a 10<sup>−

10</sup> M cholera toxin solution, 0.5 ml of a 5 mg/ml insulin solution, 12.5 ml/500 ml of a 1.2 mg/ml adenine solution, 0.5 ml of a 2.5 mg/ml transferrin+0.136 mg/ml triiodothyronine mixture, and 0.5 ml of a 10 μ

g/ml epidermal growth factor (EGF) solution,

and wherein said cells have been washed with said incubation media and fresh incubation media applied within one hour prior to said incubation for 24 hours.

3. The composition of claim 1, wherein said cells that produce EPO have a decrease in EPO expression as measured by a 2- to 20-fold decrease in EPO mRNA after incubation of said cells at 70% confluency for 20 hours:

under hypoxic conditions for 10 hours, said hypoxic conditions being;

a humidified incubator at 37°

C., at atmospheric pressure, and with 1% O₂, 5% CO₂ and 94% N₂,

followed by incubation for 10 hours under normoxic conditions of;

a humidified incubator at 37°

C., at atmospheric pressure, and with 5% CO₂ and 95% atmospheric air;

as compared to incubation for 20 hours under said hypoxic conditions given above,

wherein said incubation media is a 1;

1 mixture of keratinocyte serum-free medium (KSFM) and premixed Dulbecco'"'"'s Modified Eagle'"'"'s Medium (DMEM) based media, wherein said DMEM based media is ¾

DMEM and ¼

HAM'"'"'S F12 nutrient mixture supplemented with 5% fetal bovine serum (FBS), 1% Penicillin/Streptomycin, 1% glutamine 100×

, 1 ml of 0.4 μ

g/ml hydrocortisone, 0.5 ml of a 10<sup>−

10</sup> M cholera toxin solution, 0.5 ml of a 5 mg/ml insulin solution, 12.5 ml/500 ml of a 1.2 mg/ml adenine solution, 0.5 ml of a 2.5 mg/ml transferrin+0.136 mg/ml triiodothyronine mixture, and 0.5 ml of a 10 μ

g/ml epidermal growth factor (EGF) solution,

and wherein said cells have been washed with said incubation media and fresh incubation media applied within one hour prior to said incubation for 20 hours.

4. The composition according to claim 1, wherein said subject is a human subject.

5. The composition according to claim 4, wherein the pharmaceutically acceptable carrier further comprises a solution selected from an aqueous buffer and tissue culture media.

6. The composition according to claim 1, wherein the pharmaceutically acceptable carrier further comprises a solution selected from an aqueous buffer and tissue culture media.

7. The composition of claim 1, wherein said differentiated mammalian renal cells have been passaged in vitro from 2 to 6 times.

8. The composition of claim 1, wherein said hydrogel comprises collagen.

9. The composition of claim 1, wherein said hydrogel comprises one or more extracellular matrix analogs.

10. The composition of claim 1, wherein said hydrogel comprises gelatin.